Search

Long-term bladder drainage: blessing or disaster in disguise

Chronic bladder dysfunction occurs in many neurologic disorders e.g. multiple sclerosis, Parkinson’s disease, stroke, etc. Suprapubic catheters (SPC) are inserted every day and every urology department has a pool of ‘difficult’ patients who keep coming back. This paper compares SPCs...

Reflux oesophagitis and risk of interstitial cystitis: is there a link?

This study aims to explore the potential link between reflux oesophagitis (RE) and interstitial cystitis / bladder pain syndrome (IC/BPS). IC/BPS is a chronic disease which is difficult to diagnose and treat. Two percent of the population may be affected....

Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study

This study examined a cohort of non-statin using patients who participated in the REDUCE study. The REDUCE study included men who had an elevated prostate specific antigen (PSA) and a negative baseline prostate biopsy who then underwent year two and...

Guideline of guidelines – testosterone therapy for testosterone deficiency

The authors conducted an internet search and analysed guidelines for testosterone therapy (TTh) produced by the American Urological Association (AUA), European Association of Urology (EAU), American Association of Clinical Endocrinologists (AACE), British Society of Sexual Medicine (BSSM), Endocrine Society (ES),...

Advanced prostate cancer and chemotherapy

The treatment pathway for advanced prostate cancer is both puzzling and complex and varies from centre to centre in the UK. The National Prostate Cancer Audit Report 2019 for England and Wales shows that only a quarter of men with...

COVID-19: cancer and corticosteroids

Under the prevailing COVID-19 crisis, this article is well worth reading. The current World Health Organization (WHO) guidance is not to start steroids in cancer cases, but there is no clear evidence of risks with steroids in cancer patients having...

Increased use of active surveillance for men with intermediate risk prostate cancer

The optimal management of men with intermediate risk prostate cancer remains unclear and continues to be debated. The authors interrogate the US National Cancer Database for 176,122 men diagnosed with intermediate risk prostate cancer between 2010 and 2016. Of these...

The urinary microbiome in IC/BPS: more complicated than we imagined

The concluding statement of this short review states, “the study of the urinary microbiome and its impact on urological disease, including IC/BPS, is in its infancy.” A lot has been said on this subject in recent years, but this, in...